ArticleExpert opinion on drug metabolism & toxicology2015
Tissue-engineered blood vessels as promising tools for testing drug toxicity.
Article in Expert opinion on drug metabolism & toxicology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 22 citations in OpenAlex.
- Endothelial Cells Increase Mesenchymal Stem Cell Differentiation in Scaffold-Free 3D Vascular Tissue.Tissue engineering. Part A · 2025Article
- Comparison of Silk Hydrogels Prepared via Different Methods.Polymers · 2023Article
- Modelling Human Physiology on-Chip: Historical Perspectives and Future Directions.Micromachines · 2021Review
- Biofabrication of tissue engineering vascular systems.APL bioengineering · 2021Review
- Measuring and regulating oxygen levels in microphysiological systems: design, material, and sensor considerations.The Analyst · 2019Review
- Collagen-Based Tissue Engineering Strategies for Vascular Medicine.Frontiers in bioengineering and biotechnology · 2019Review
- Assembly of Tissue-Engineered Blood Vessels with Spatially Controlled Heterogeneities.Tissue engineering. Part A · 2018Article
- Does low volume high-intensity interval training elicit superior benefits to continuous low to moderate-intensity training in cancer survivors?World journal of clinical oncology · 2018Article
- A Tissue Engineered Blood Vessel Model of Hutchinson-Gilford Progeria Syndrome Using Human iPSC-derived Smooth Muscle Cells.Scientific reports · 2017Article
- Cellular Self-Assembly with Microsphere Incorporation for Growth Factor Delivery Within Engineered Vascular Tissue Rings.Tissue engineering. Part A · 2017Article
- Article
- Human Vascular Microphysiological System for in vitro Drug Screening.Scientific reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Drug-induced vascular injury (DIVI) is a serious problem in preclinical studies of vasoactive molecules and for survivors of pediatric cancers. DIVI is often observed in rodents and some larger animals, primarily with drugs affecting vascular tone, but not in humans; however, DIVI observed in animal studies often precludes a drug candidate from continuing along the development pipeline. Thus, there is great interest by the pharmaceutical industry to identify quantifiable human biomarkers of DIVI. Small-scale endothelialized tissue-engineered blood vessels using human cells represent a promising approach to screen drug candidates and develop alternatives to cancer therapeutics in vitro. We identify several technical challenges that remain to be addressed, including high-throughput systems to screen large numbers of candidates, identification of suitable cell sources and establishing and maintaining a differentiated state of the vessel wall cells. Adequately addressing these challenges should yield novel platforms to screen drugs and develop new therapeutics to treat cardiovascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.